跳至主要内容
临床试验/NCT00378768
NCT00378768已完成2 期

A Phase II Study of Thymoglobulin in Patients With Multiple Myeloma Who Are Candidates for Allogeneic or Autologous Stem Cell Transplant

Fred Hutchinson Cancer Center2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2005年11月最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
12
试验地点
2
主要终点
Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks

研究概览

简要总结

RATIONALE: Biological therapies, such as antithymocyte globulin, may stimulate the immune system in different ways and stop cancer cells from growing.

PURPOSE: This phase II trial is studying how well antithymocyte globulin works in treating patients undergoing stem cell transplant for multiple myeloma.

详细描述

OBJECTIVES:

Primary

  • Determine the response rate at 4 weeks in patients with multiple myeloma treated with anti-thymocyte globulin at least 4 to 6 weeks prior to undergoing conditioning therapy for allogeneic or autologous stem cell transplantation.

Secondary

  • Determine the toxicity of this drug, in terms of formation of antirabbit antibodies, in these patients.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Response rate, as measured by International Bone Marrow Transplant Registry (IBMTR)/European Group for Blood and Marrow Transplantation (EBMT) Response Criteria, at 4 weeks

次要结局

  • Toxicity as assessed by NCI CTC v2.0
  • Formation of antirabbit antibodies

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验